A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumours

Official Title

A Phase II, Open-Label, Multicentre, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumours

Summary:

This study will evaluate the efficacy and safety of multiple biomarker-driven treatments in patients with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary peritoneal tumours. Enrollment will take place in two phases: a preliminary phase followed by a potential expansion phase.

Trial Description

Primary Outcome:

• Confirmed Objective Response Rate (ORR)

• Duration of Response (DOR)
• Disease Contral Rate (DCR)
• Progression Free Survival (PFS)
• Overall Survival (OS)
• Confirmed ORR as Determined by IRC (Independent Review Committee)
• DOR as Determined by IRC
• DCR as Determined by IRC
• PFS as Determined by IRC
• Percentage of Participants With Adverse Events
• Percentage of Participants With ADA-Positive and ADA-Negative to Atezolizumab
• Number of Participants With ADA-Positive and ADA-Negative to Atezolizumab

View this trial on ClinicalTrials.gov